3B Blackbio DX Ltd

Q1 FY25Healthcare Services

3B Blackbio DX Q1 FY25 earnings call: Revenue & Margins

Q1 FY25 investor presentation: what the company reported on revenue, margins and projects.

Price₹1,406

Market cap₹1.1K Cr

P/E20.4

Updated24 Sept 2026

Read4 min read

Based on 3B Blackbio DX Ltd's Q1 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.

The short version

Total consolidated revenue for Q1 FY 2024-25: ₹2,312.50 lakh, up from ₹1,724.32 lakh in Q1 FY 2023-24. - Diagnostics business standalone (non-COVID) sales rose to ₹1,496.92 lakh in Q1 FY 2024-25 from ₹1,054.13 lakh in Q1 FY 2023-24 (~42% increase). - Molecular diagnostic (MDx) kits export sales increased to ₹346.93 lakh in Q1 FY 2024-25 from ₹163.51 lakh in Q1 FY 2023-24 (+112%). - UK subsidiary TRUPCR® Europe Ltd. EBITDA Q1 FY 2024-25: Rs.

From 3B Blackbio DX Ltd's Q1 FY25 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

Total consolidated revenue for Q1 FY 2024-25: ₹2,312.50 lakh, up from ₹1,724.32 lakh in Q1 FY 2023-24.
Diagnostics business standalone (non-COVID) sales rose to ₹1,496.92 lakh in Q1 FY 2024-25 from ₹1,054.13 lakh in Q1 FY 2023-24 (~42% increase).
Molecular diagnostic (MDx) kits export sales increased to ₹346.93 lakh in Q1 FY 2024-25 from ₹163.51 lakh in Q1 FY 2023-24 (+112%).
UK subsidiary TRUPCR® Europe Ltd. revenue grew 85% year-on-year in Q1 FY 2024-25 (from GBP 163,887 to GBP 309,204).
Non-COVID sales effective growth for Q1 FY 2024-25 is approx. 40%, aligned with expected 20-25% growth outlook.

2 more points management made on revenue & sales performance

Profitability & Margins

EBITDA Q1 FY 2024-25: Rs. 1,458.53 lakh
EBITDA Q1 FY 2023-24: Rs. 898.43 lakh
EBITDA YoY Increase: Rs. 560.10 lakh (~62.4% increase)
Profit After Tax (PAT) Q1 FY 2024-25: Rs. 1,132.75 lakh
PAT Q1 FY 2023-24: Rs. 696.51 lakh
PAT YoY Increase: Rs. 436.24 lakh (~62.6% increase)
Revenue from Operations Q1 FY 2024-25: Rs. 1,694.44 lakh (Diagnostics Business)
Revenue from Operations Q1 FY 2023-24: Rs. 1,202.89 lakh

2 more points management made on profitability & margins

See what 3B Blackbio DX Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

The company is continuously investing in additional manufacturing and R&D facilities/capacities to support existing business verticals (Page 34).
It aims to expand production capabilities but no specific capex amounts, new plant details, or timelines are provided.
Funds will also be deployed in a joint venture created in Manchester, UK, depending on need (Page 34).
The Manchester site houses sales, marketing, technical support, and R&D, with projected growth of 40%-50% for the fiscal year (Page 23).

2 more points management made on capital expenditure plans

Top-ranked in Healthcare Services

Ranked on what management guided this quarter

5x potential

1Health X Platform₹919 Cr

Rev 1Mar 1

2Chandan Healthca₹590 Cr

Rev 1Mar 3

3₹66.2K Cr

Rev 2Mar 1

4₹1.8K Cr

Rev 2Mar 2

5₹649 Cr

Rev 2Mar 2

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

The presentation does not explicitly mention any recent or planned fundraising through debt or equity.
On page 34, it states the company will consider acquisitions if financially viable, otherwise may look at share buyback later, indicating no immediate equity raise.
There is no mention of new borrowings or changes in net debt throughout the document.

2 more points management made on fundraising & capital structure

See what 3B Blackbio DX Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The investor presentation does not explicitly mention specific figures or details regarding the order book, order inflow, or pending orders. However, it provides related insights as follows: - The company has signed over 15 long-term contracts (2-3 years) under a Reagent-Rental Model, contributing to projected business of 20%-25% in the current and coming years (Page 33). - These contracts imply stable and predictable business operations but no direct order book or inflow figures are given.

- The presentation highlights a substantial increase in export sales and overall revenue growth but does not quantify pending or new orders (Pages 5, 13, 18). - No explicit mention of order backlog or pending orders is found in the slides reviewed. In summary, the presentation emphasizes long-term contracts and revenue growth but does not report order book, order inflow, or pending orders specifically.

2 more points management made on order book & pipeline

3B Blackbio DX Ltd — Quarterly revenue & net profit

Revenue Net profit

Sep 2024

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Reported quarterly figures (₹ Cr). Latest: revenue ₹50 Cr, net profit ₹22 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What 3B Blackbio DX Ltd's management said in earlier quarters

Compare:vs Apollo Hospitals Enterprise Ltd vs Max Healthcare vs Manipal Health

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were 3B Blackbio DX Ltd Q1 FY25 results?

What is 3B Blackbio DX Ltd share price analysis?

3B Blackbio DX Ltd currently shows a neutral. The stock trades at a P/E of 20.4 with a market cap of ₹1,132 Cr. Investors should review the full earnings analysis for detailed insights.

Is 3B Blackbio DX Ltd planning capital expenditure?

The company is continuously investing in additional manufacturing and R&D facilities/capacities to support existing business verticals (Page 34).

Keep 3B Blackbio DX Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.